Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 800 results for "tyrosine"

Time to Definitive Failure to the First Tyrosine Kinase Inhibi...

Abstract Purpose In 2004, we started an intergroup randomized trial of adjuvant imatinib versus no further therapy after R0-R1 surgery patients with localized, high- or intermediate-risk GI stromal tumor (GIST). Patients and Methods Patients ... Journal of Clinical Oncology, 1 week ago

Global Non-Tyrosine Kinase Inhibitors in Oncology, 2015-2025 - mTOR inhibitors (53%) and RAF/MEK inhibitors (46%) are the main contributors to the market

Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( ) has announced the addition of the "Non-Tyrosine Kinase Inhibitors in Oncology, 2015 - 2025" report to their offering. ...
 Wall Street Business Network2 weeks ago

Threshold Pharmaceuticals, Inc. Release: Preclinical Studies Find That Tarloxotinib May Overcome Resistance To EGFR Tyrosine Kinase Inhibitors

) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD ) today announced new preclinical data demonstrating that tarloxotinib bromide*, or tarloxotinib, may overcome resistance to first- and second- and third-generation epidermal growth factor receptor ...
 BioSpace2 weeks ago Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors  Wall Street Select2 weeks ago THRESHOLD PHARMACEUTICALS : Preclinical Studies Find That Tarloxotinib May Overcome Resistance to EGFR Tyrosine Kinase Inhibitors  4 Traders2 weeks ago

China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi

Shanghai-based ZAI Lab has in-licensed China rights for HM61713, a tumor-targeting EGFR tyrosine kinase inhibitor from South Korea's Hanmi , which has racked up an impressive string of license deals this year. Terms of the deal were not disclosed, ...
 Fierce CRO19 hours ago Zai Lab And Hanmi Pharma Execute A License Agreement To Develop Novel EGFR Targeted Therapy For Lung Cancer In China  BioSpace1 day ago ZAI Lab Acquires China Rights to Hanmi Lung Cancer Drug  Financial Content1 day ago ZAI Lab and Hanmi Execute a License Agreement to Develop Novel EGFR Targeted Therapy for Lung Cancer in China  Tamar Securities2 days ago
Cancer Therapy Advisor

Alectinib shows promise in crizotinib-refractory ALK-rearranged NSCLC

FROM JOURNAL OF CLINICAL ONCOLOGY Alectinib, an oral, small-molecule, ATP-competitive tyrosine kinase inhibitor of ALK, demonstrated good clinical activity in crizotinib-refractory patients with advanced nonsmall-cell lung cancer (NSCLC) ...
 PM 3601 day ago Alectinib Highly Active, Safe in Advanced Crizotinib-refractory ALK+ NSCLC  Cancer Therapy Advisor1 day ago
Palestine Telegraph

Why we always overdo Thanksgiving dinner: Scientists reveal what happens to our bodies when we overeat

When the hormone peptide tyrosine starts working, we get the sensation of being full. However, this takes 30 minutes to take effect, according to a dietician at the University of Texas.
 Palestine Telegraph1 day ago

Reactions of 1,3-Diketones with a Dipeptide Isothiazolidin-3-one: Toward Agents That Covalently Capture Oxidized Protein Tyrosine Phosphatase 1B

Protein tyrosine phosphatase 1B (PTP1B) is a validated therapeutic target for the treatment of type 2 diabetes; however, the enzyme has been classified by some as an undruggable target. Here we describe studies directed toward the development of ...
 Journal of Organic Chemistry1 day ago

iwNHL 2015: Ibrutinib, Bruton's tyrosine kinase inhibitor, for non-Hodgkin lymphoma

Description: At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Thomas J. Kipps, MD, PhD, of the University of California, San Diego, San Diego, CA, discusses the currently available data on the safety and efficacy of ...
 Oncology Tube2 days ago

Novel transcripts reveal a complex structure of the human TRKA gene and imply the presence of multiple protein isoforms

Background: Tropomyosin-related kinase A (TRKA) is a nerve growth factor (NGF) receptor that belongs to the tyrosine kinase receptor family. It is critical for the correct development of many types of neurons including pain-mediating sensory neurons ...
 MyInforms1 week ago

A New Use for Nilotinib…

Tyrosine kinase inhibitors (TKIs) have changed the treatment paradigm for patients with chronic myelogenous leukemia (CML), and new research suggests one of the agents could potentially do the same for patients with Parkinson's disease. Researchers ...
 Oncology Times1 week ago Defining Who Benefits from HSCT in CML  Oncology Times1 week ago Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia  Plosone.org1 week ago Findings from University Hospital Yields New Findings on Myeloid Leukemia (Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia...  Pharmacy Choice2 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less